Have you guys been reading any of the threads? if so you would...

Have you guys been reading any of the threads? if so you would understand the complaints inside out.

The company trying to save money by not getting a costly CEO ?! Embark Base fee alone (this is not including performance rights, and percentage of returns they will take, just base fees alone) are higher than any CEO of all ASX listed Cannabis companies, this is a FACT, this is not cost saving, we are paying higher than any ASX listed CEO in the Cannabis space as base fee alone, and by the sound of it they are going to get a CEO in the future , so not only pay more than any CEO to Embark but we probably got one of Micheal Curtis friends coming in the future to take a nice CEO salary too.

The argument of being good investments has some legs, but they sold out of the best performing one already (Medipharms), thats where the cash came from, and Harvest has got a good future but we are not following harvest.

Embark being chosen on its own merits is very suspect too, they have no history in asset management, so what exact merits does it have besides their high fees and insider ties to MMJ directors. Dodgy.